Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 3/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL289857 | 0.90 | CYP3A4 (0.45) | CYP3A4TDP1ALDH1A1ALOX15TSHR | |
| Hydrochloric Acid SCHEMBL31568007 | 0.87 | CYP3A4 (0.43) | CYP3A4TDP1ALDH1A1ALOX15TSHR | |
| SCHEMBL14696690 | 0.87 | CYP3A4 (0.43) | CYP3A4TDP1ALDH1A1ALOX15TSHR | |
| Hydrochloric Acid SCHEMBL31467528 | 0.87 | CYP3A4 (0.43) | CYP3A4TDP1ALDH1A1ALOX15TSHR | |
| SCHEMBL18796532 | 0.87 | CYP3A4 (0.43) | CYP3A4TDP1ALDH1A1ALOX15TSHR | |
| SCHEMBL3645144 | 0.87 | CYP3A4 (0.43) | CYP3A4TDP1ALDH1A1ALOX15TSHR | |
| Bromide SCHEMBL28700347 | 0.87 | CYP3A4 (0.43) | CYP3A4TDP1ALDH1A1ALOX15TSHR | |
| SCHEMBL19093066 | 0.87 | CYP3A4 (0.43) | CYP3A4TDP1ALDH1A1ALOX15TSHR | |
| SCHEMBL1743625 | 0.86 | CYP3A4 (0.38) | CYP3A4TDP1ALDH1A1ALOX15TSHR | |
| SCHEMBL1304876 | 0.86 | CYP3A4 (0.38) | CYP3A4TDP1ALDH1A1ALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114213210-B | Preparation method of decabromodiphenyl ethane | 寿光卫东化工有限公司 | 2023-11-10 | — | — | CN | claimed |
| CN-114213210-A | Preparation method of decabromodiphenylethane | 寿光卫东化工有限公司 | 2022-03-22 | — | — | CN | claimed |
| US-20170197944-A1 | PROCESS FOR THE PREPARATION OF LEDIPASVIR | Optimus Drugs, LLC (IN) | 2017-07-13 | — | — | US | claimed |
| WO-2017072596-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LEDIPASVIR | OPTIMUS DRUGS (P) LTD (IN) | 2017-05-04 | — | — | WO | claimed |
| CN-114213210-B | Preparation method of decabromodiphenyl ethane | 寿光卫东化工有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-114213210-A | Preparation method of decabromodiphenylethane | 寿光卫东化工有限公司 | 2022-03-22 | — | — | CN | disclosed |
| US-10118912-B2 | Process for the preparation of Ledipasvir | OPTIMUS DRUGS PRIVATE LTD. (IN) | 2018-11-06 | — | — | US | disclosed |
| US-20170197944-A1 | PROCESS FOR THE PREPARATION OF LEDIPASVIR | Optimus Drugs, LLC (IN) | 2017-07-13 | — | — | US | disclosed |
| WO-2017072596-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LEDIPASVIR | OPTIMUS DRUGS (P) LTD (IN) | 2017-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10118912-B2 | Process for the preparation of Ledipasvir | SAMHD1, POLI, PNP | CYP3A4 43/4885TDP1 727/4885ALDH1A1 1979/4885 |
| US-20170197944-A1 | PROCESS FOR THE PREPARATION OF LEDIPASVIR | SAMHD1, POLI, PNP | CYP3A4 43/4885TDP1 727/4885ALDH1A1 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.